However, in the i.p. ovarian carcinoma xenograft model, the levels of vascular endothelial growth factor, platelet derived growth factor and basic fibroblast growth factor in i.p. fluid were not affected by CpG-ODN1826 treatment [15], suggesting other possible mechanisms through which the agent inhibits ascites development. This evidence concerns the gene VEGFA and ovarian carcinoma.